tiprankstipranks
Trending News
More News >
Verici Dx Plc (GB:VRCI)
:VRCI
Advertisement

Verici Dx Plc (VRCI) Price & Analysis

Compare
3 Followers

VRCI Stock Chart & Stats


Financials

Options Prices

Currently, No data available
---

Ownership Overview

0.67%0.02%99.98%
0.67%
Insiders
0.02%
Mutual Funds
― Other Institutional Investors
99.98% Public Companies and
Individual Investors

VRCI FAQ

What was Verici Dx Plc’s price range in the past 12 months?
Verici Dx Plc lowest share price was 1.00p and its highest was 8.50p in the past 12 months.
    What is Verici Dx Plc’s market cap?
    Verici Dx Plc’s market cap is £2.73M.
      When is Verici Dx Plc’s upcoming earnings report date?
      Verici Dx Plc’s upcoming earnings report date is Sep 15, 2025 which is in 62 days.
        How were Verici Dx Plc’s earnings last quarter?
        Currently, no data Available
        Is Verici Dx Plc overvalued?
        According to Wall Street analysts Verici Dx Plc’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
          Does Verici Dx Plc pay dividends?
          Verici Dx Plc does not currently pay dividends.
          What is Verici Dx Plc’s EPS estimate?
          Verici Dx Plc’s EPS estimate for its next earnings report is not yet available.
          How many shares outstanding does Verici Dx Plc have?
          Verici Dx Plc has 242,541,470 shares outstanding.
            What happened to Verici Dx Plc’s price movement after its last earnings report?
            Currently, no data Available
            Which hedge fund is a major shareholder of Verici Dx Plc?
            Currently, no hedge funds are holding shares in GB:VRCI

            Company Description

            Verici Dx Plc

            Verici Dx plc, an immuno-diagnostics development company, focuses on the kidney transplantation market. The company develops prognostic and diagnostic tests for kidney transplant patients. Its in-development tests include Clarava, a pre-transplant prognosis test for the risk of early acute rejection; Tuteva, a post-transplant test that focuses on acute cellular rejection; and Protega, a liquid biopsy that aims to predict the risk of fibrosis and long-term graft failure. The company was incorporated in 2020 and is based in Penarth, the United Kingdom.
            Similar Stocks
            Company
            Price & Change
            Follow
            Genedrive
            Proteome Sciences
            BSF Enterprise PLC
            Abingdon Health PLC
            GENinCode UK Ltd.
            Popular Stocks
            What am I Missing?
            Make informed decisions based on Top Analysts' activity
            Know what industry insiders are buying
            Get actionable alerts from top Wall Street Analysts
            Find out before anyone else which stock is going to shoot up
            Get powerful stock screeners & detailed portfolio analysis